10-04-2022 | Healthcare costs | News
The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.
09-23-2022 | EASD 2022 | Conference coverage | News
The latest update to the ADA and EASD hyperglycemia management consensus report places a strong emphasis on holistic, person-centered care for type 2 diabetes.
09-21-2022 | EASD 2022 | Conference coverage | News
Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.
10-06-2022 | SGLT2 inhibitors | News
09-30-2022 | Cancer | News
Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.
Get the latest results and insights from the researchers.
09-22-2022 | EASD 2022 | Conference coverage | News
Get the latest developments in diabetes delivered straight to your inbox